SANA’s thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset.
Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips
SANA’s thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset.